Multiple approaches to reduce reconstitution time of lyophilized drug products with high protein concentration.

Xiaozhang Zhang, Ningning Zhou, Chunsheng Yang, Zhaowei Jin, Jeremy Guo
Author Information
  1. Xiaozhang Zhang: Drug Product Development, WuXi Biologics (Shanghai) Co., Ltd, 190 Hedan Road, Waigaoqiao Free Trade Zone, Shanghai, 200131, China.
  2. Ningning Zhou: Drug Product Development, WuXi Biologics (Shanghai) Co., Ltd, 190 Hedan Road, Waigaoqiao Free Trade Zone, Shanghai, 200131, China.
  3. Chunsheng Yang: Drug Product Development, WuXi Biologics (Shanghai) Co., Ltd, 190 Hedan Road, Waigaoqiao Free Trade Zone, Shanghai, 200131, China.
  4. Zhaowei Jin: Drug Product Development, WuXi Biologics (Shanghai) Co., Ltd, 190 Hedan Road, Waigaoqiao Free Trade Zone, Shanghai, 200131, China.
  5. Jeremy Guo: Drug Product Development, WuXi Biologics (Shanghai) Co., Ltd, 190 Hedan Road, Waigaoqiao Free Trade Zone, Shanghai, 200131, China. ORCID

Abstract

Background: Lyophilized drug products with high protein concentration often perform long reconstitution time, which is inconvenient for clinical use. The objective of this work is to achieve short reconstitution time with multiple and combined strategies.
Methods: Here, we describe the following approaches that lead to reduction of reconstitution time, including adding annealing step, decreasing headspace pressure, decreasing protein concentration with reducing diluent volume, increasing high surface-area-to-height ratio of the cakes, increasing frequency of swirling and diluent temperature.
Results: Among these strategies, reducing diluent volume to achieve high protein concentration and reducing headspace pressure show markedly reduction of reconstitution time. Moreover, we propose combined strategies to mitigate the reconstitution time, at the same time, to achieve same target dose in clinics.
Conclusions: Therefore, this paper provides insights on the application of multiple strategies to accelerate the reconstitution of lyophilized drug products with high concentration, and facilitates their widespread clinical application.

Keywords

References

  1. J Pharm Sci. 2020 May;109(5):1681-1691 [PMID: 32070705]
  2. Pharm Res. 1997 Aug;14(8):969-75 [PMID: 9279875]
  3. Eur J Pharm Biopharm. 2018 Oct;131:70-81 [PMID: 30056143]
  4. PDA J Pharm Sci Technol. 2016 11/12;70(6):508-522 [PMID: 27974591]
  5. Eur J Pharm Biopharm. 2013 Oct;85(2):287-93 [PMID: 23702275]
  6. J Pharm Sci. 2020 Jun;109(6):1896-1904 [PMID: 32112825]
  7. J Pharm Sci. 2016 Jul;105(7):2073-85 [PMID: 27290623]
  8. J Pharm Sci. 2008 Aug;97(8):3084-99 [PMID: 17963216]
  9. Am J Hosp Pharm. 1990 Dec;47(12):2696-700 [PMID: 2278285]
  10. Antib Ther. 2021 Nov 18;4(4):262-272 [PMID: 34909579]
  11. J Pharm Sci. 2020 Jun;109(6):1905-1911 [PMID: 32135168]
  12. Food Chem. 2023 Mar 1;403:134153 [PMID: 36358064]
  13. Am J Health Syst Pharm. 2015 Mar 1;72(5):396-407 [PMID: 25694415]
  14. J Pharm Sci. 2011 Aug;100(8):3453-3470 [PMID: 21465488]
  15. J Pharm Sci. 2010 May;99(5):2256-78 [PMID: 20039389]
  16. Drug Des Devel Ther. 2021 Jan 13;15:159-170 [PMID: 33469268]
  17. Eur J Pharm Biopharm. 2021 Aug;165:361-373 [PMID: 33974974]
  18. J Pharm Sci. 2016 Jul;105(7):2249-53 [PMID: 27287517]
  19. J Pharm Sci. 2004 Jun;93(6):1390-402 [PMID: 15124199]
  20. Eur J Pharm Biopharm. 2017 Oct;119:353-360 [PMID: 28690199]

Word Cloud

Created with Highcharts 10.0.0reconstitutiontimehighconcentrationdrugproductsproteinstrategiesreducingdiluentachievemultiplecombinedapproachesheadspacepressurevolumelyophilizedclinicalreductiondecreasingincreasingapplicationBackground:LyophilizedoftenperformlonginconvenientuseobjectiveworkshortMethods:describefollowingleadincludingaddingannealingstepsurface-area-to-heightratiocakesfrequencyswirlingtemperatureResults:AmongshowmarkedlyMoreoverproposemitigatetargetdoseclinicsConclusions:ThereforepaperprovidesinsightsacceleratefacilitateswidespreadMultiplereducestrategy

Similar Articles

Cited By